UltraSight recently obtained the CE Mark for its artificial intelligence (AI)-guided software for cardiac ultrasound, expected to be available in Europe by 2023.
The company said its technology enables medical professionals, regardless of their sonography experience, to acquire diagnostic-quality ultrasound images of the heart. The technology can be used at the point of care.
UltraSight received the CE Mark following results from a clinical study held at the Sheba Medical Center in Israel. The study found that guidance from the technology allowed novice users to obtain diagnostic-quality cardiac images in all patients. The study was conducted using the Lumify ultrasound device from Philips.
"Point of care ultrasound can be a very useful tool for intensive care unit (ICU) physicians. Some key hemodynamic measurements, such as Left Ventricular Outflow Tract Velocity Time Integral (LVOT VTI), provide invaluable help to guide fluid therapy. However, some physicians are still reluctant to use it because they consider this measurement a competence reserved for advanced ultrasound operators," said Prof. Bernard Cholley, ICU department head at the Georges Pompidou Hospital Paris in a press statement from the company.
